Leading the Way in Life Science Technologies

GEN Exclusives

More »

April 1, Vol. 32, No. 7

  • Feature Articles

    • Exploiting Gene-Expression Data
    • Kathy Liszewski
    • The field of gene expression continues to grow and evolve Commonly used technologies such as microarrays are packing higher densities in a smaller footprint, and qPCR is becoming more accurate and reproducible with new guidelines in place... more »
    • Improving Cell Culture Optimization
    • John Russell
    • With much of the low-hanging fruit in cell culture optimization already plucked, progress today is centering on how to produce more complex molecules, improving bioproduction consistency and efficiency, and developing better predictive tools for media and processing performance... more »
    • Small-Scale Modeling and Predicting
    • Vicki Glaser
    • Optimizing production efficiency of a bioprocess to yield high titers of a desired recombinant protein or monoclonal antibody requires great attention to detail This begins at initial design and testing of a small-scale process right on through scale-up to industrial-scale ... more »
    • Regenerative Medicine Looks to the Future
    • Jeffery Herman, Ph.D.
    • After nearly a decade-long federal moratorium on embryonic stem cell research, regenerative medicine took a serious hit Yet sometimes from adversity comes innovation Like-minded regenerative medicine industry leaders illustrated this point at the recent “New York Stem Cell” summit With ... more »
    • Stem Cell Initiatives at Sanford Consortium for ...
    • The California Institute for Regenerative Medicine (CIRM), a state granting agency created by a voter-approved ballot initiative in 2004, gave $43 million toward the construction of a new research facility that just opened its doors last fall in the Torrey ... more »
  • Columns

    • People in the News
    • Silence Therapeutics promoted Anthony David Sedgwick, PhD , to CEO from CBO Dr Sedgwick has worked at Silence since September 2011 Prior to that, he was CEO at Novacta and chairman of Plastid He has also held the position of ... more »
    • Panel Wrestles with WGS Ethics
    • Alex Philippidis
    • The US Presidential Commission for the Study of Bioethical Issues is grappling with many of the ethical issues arising from the falling price—and resulting potential for increased use—of whole genome sequencing in clinical care The aim is to find the ... more »
    • Gold Rush at the Invention Mine
    • Tom Tuytschaevers
    • Many companies have more inventions than they recognize, and each unrecognized invention is a missed opportunity and potentially a wasted asset Fortunately, capturing unrecognized inventions through “invention mining” is easy and efficient, and should be a regular part of any ... more »
    • Managing a Deluge of Sequencing Data
    • Carol Potera
    • Computer scientists founded Appistry in 2001 to “solve big data analytical problems,” says Kevin Haar, CEO The firm’s cloud-based computing technology helps customers like FedEx, financial institutions, and government agencies solve problems related to the analysis of data-intensive applications... more »
    • 2012 Has the Makings of a Breakout Year
    • Eugene Rozelman
    • Numerous biotechs are set to turn the card on clinical trial data readouts that should drive significant value inflection for their shareholders A number of key regulatory decisions that will likely impact investor sentiment are also on the calendar for ... more »
    • Tech Transfer Efforts Show Successes but Investm...
    • Like every other US state, Maryland has been scrambling to balance its budget and cut spending since the economy soured in 2008 Yet, the state is considering spending more to stoke technology transfer efforts by universities and other institutions, hoping ... more »
    • Gene Therapy Briefs
    • European Medicines Agency (EMA) published a reflection paper of regulatory considerations for specific gene therapy medicinal products (GTMPs) whose characteristics have been changed at various stages during clinical development, based on scientific discussions within EMA committees/working parties. Among areas discussed ... more »